Clinically active Crohn's disease in the presence of a low C-reactive protein
- PMID: 16497618
- DOI: 10.1080/00365520500217118
Clinically active Crohn's disease in the presence of a low C-reactive protein
Abstract
Objective: Clinical interest in C-reactive protein (CRP) -- a component of the innate immune system -- has focused mainly on its worth as an indicator of disease activity. There has been a resurgence of interest in CRP in the Crohn's disease (CD) literature because several trials of new treatments for active CD have been characterized by both a large proportion of patients with low CRP (<10 mg/l) at entry to the trials and by a negative therapeutic outcome. It is therefore of interest to study the clinical characteristics of patients who are thought to have at the same time both active CD and a low CRP.
Material and methods: Patients were prospectively recruited as part of the Brisbane IBD clinical and research programme. Subjects were included in the low CRP group only if there were complete datasets for CRP on all occasions of active CD, and CRP was < 10 mg/l. Active disease was defined as CD activity index (CDAI)>200. The low CRP group was compared with patients in the raised CRP group for a range of clinical variables as well as the major NOD2 variants.
Results: There were data sets for 223 CD patients, with a mean disease duration of 12 years. Of these, 22 patients fulfilled the criteria for low CRP. The low CRP group (group 1) showed significant differences for disease site (p<0.01) and for BMI (p=0.006) compared to the raised CRP group (group 2). Specifically, group 1 had a predominance of pure ileal disease (95% versus 53%) and lack of pure colonic disease (0% versus 24%) compared to group 2, and their BMI was significantly lower (20.3 kg/m(2) versus 25.0 kg/m(2)). Groups 1 and 2 did not differ with respect to Vienna behaviour at diagnosis, smoking, appendicectomy, extra-intestinal manifestations of CD, or NOD2 SNP variants. There was a trend for low CRP patients with previous ileal resection to evolve to a stricturing phenotype. Fat wrapping was noted in 11/13 (85%) of low CRP patients undergoing ileal resections.
Conclusions: Patients with CD and a persistently low CRP in the face of active disease were characterized by an almost exclusive ileal disease distribution and a low BMI, compared to those with a raised CRP. These patients had a similar frequency and distribution of NOD2/CARD15 variants. Stricturing (v inflammatory or penetrating) behaviour may explain some low CRP. Despite the abnormally low BMI, fat wrapping was noted in the majority of low CRP patients undergoing ileal resection.
Comment in
-
C-reactive protein: informative or misleading marker of Crohn's disease?Inflamm Bowel Dis. 2007 Apr;13(4):501-2. doi: 10.1002/ibd.20123. Inflamm Bowel Dis. 2007. PMID: 17352381 No abstract available.
Similar articles
-
Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease.Clin Gastroenterol Hepatol. 2006 Jul;4(7):882-7. doi: 10.1016/j.cgh.2006.02.003. Epub 2006 Apr 19. Clin Gastroenterol Hepatol. 2006. PMID: 16630759
-
Serum measurements of pancreatitis associated protein in active Crohn's disease with ileal location.Gastroenterol Clin Biol. 2002 Jan;26(1):23-8. Gastroenterol Clin Biol. 2002. PMID: 11938036
-
Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.Am J Gastroenterol. 2008 Jan;103(1):162-9. doi: 10.1111/j.1572-0241.2007.01556.x. Epub 2007 Oct 4. Am J Gastroenterol. 2008. PMID: 17916108
-
CARD15 mutations in Dutch familial and sporadic inflammatory bowel disease and an overview of European studies.Eur J Gastroenterol Hepatol. 2007 Jun;19(6):449-59. doi: 10.1097/01.meg.0000236887.44214.6a. Eur J Gastroenterol Hepatol. 2007. PMID: 17489054 Review.
-
Is it time to re-classify Crohn's disease?Best Pract Res Clin Gastroenterol. 2004;18 Suppl:99-106. doi: 10.1016/j.bpg.2004.06.018. Best Pract Res Clin Gastroenterol. 2004. PMID: 15588801 Review.
Cited by
-
Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn's disease, and ulcerative colitis patients.Inflamm Bowel Dis. 2013 May;19(6):1139-48. doi: 10.1097/MIB.0b013e318280b19e. Inflamm Bowel Dis. 2013. PMID: 23518807 Free PMC article.
-
New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes.Inflamm Bowel Dis. 2016 Dec;22(12):2956-2965. doi: 10.1097/MIB.0000000000000903. Inflamm Bowel Dis. 2016. PMID: 27763951 Free PMC article. Review.
-
Current and future diagnostic approaches: from serologies to imaging.Curr Gastroenterol Rep. 2007 Dec;9(6):489-96. doi: 10.1007/s11894-007-0065-5. Curr Gastroenterol Rep. 2007. PMID: 18377802 Review.
-
Use of blood based biomarkers in the evaluation of Crohn's disease and ulcerative colitis.World J Gastrointest Endosc. 2015 Nov 25;7(17):1233-7. doi: 10.4253/wjge.v7.i17.1233. World J Gastrointest Endosc. 2015. PMID: 26634038 Free PMC article.
-
APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid.J Alzheimers Dis. 2021;79(2):511-530. doi: 10.3233/JAD-200747. J Alzheimers Dis. 2021. PMID: 33337362 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous